Neurocrine(US:NBIX) ZACKSยท2025-10-24 17:01Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Neurocrine Biosciences (NBIX) - Neurocrine Biosciences currently holds a Momentum Style Score of B, indicating a favorable momentum outlook [3] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [4] Performance Metrics - Over the past week, NBIX shares increased by 2.53%, while the Zacks Medical - Drugs industry remained flat [6] - In the last month, NBIX's price change was 1.97%, outperforming the industry's 1.66% [6] - Over the past quarter, NBIX shares rose by 12.04%, and over the last year, they increased by 24.37%, compared to the S&P 500's gains of 6.22% and 17.55%, respectively [7] Trading Volume - The average 20-day trading volume for NBIX is 815,114 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the last two months, three earnings estimates for NBIX have been revised upward, while none have been revised downward, increasing the consensus estimate from $4.41 to $4.49 [10] - For the next fiscal year, two estimates have moved up, while one has been revised down [10] Conclusion - Considering the positive momentum indicators and earnings outlook, NBIX is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]